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ABSTRACT Sera of patients with breast cancer, of healthy
women from the United States, East India, East Africa, and
China, and of healthy women of American and Parsi families in
which breast cancer occurred in several family members were
assayed for levels of antibody reactive with the murine mammary
tumor virus (MuMTV) by an enzyme-linked immunosorbent assay.
Increased levels of antibody to MuMTV (absorbance -0.4) were
found in sera of 18.6% ofAmerican patients with breast cancer and
of 2.8% of healthy American women and in 38% of patients from
India and 61.9% from East Africa (healthy, 26.9%). In contrast,
antibody reactive with MuMTV was found in <5 of women with
breast cancer from mainland China (healthy Chinese, 5.0%). Dif-
ferences in serum MuMTV antibody levels between breast cancer
patients in the four groups were found to be significant (P <
0.0001). Studies of two families from the United States and of one
Parsi family from India with genetic propensity to breast cancer
showed that high levels ofantibody to MuMTV were found in 33%,
71%, and 23% of healthy family members, respectively. The an-
tibody to MuMTV was readily absorbed with purified MuMTV
and gp52. In contrast, fetal calf serum, murine type C retrovi-
ruses, or erythrocytes from various species failed to absorb the
antibody.
A relationship between human breast cancer and murine mam-
mary tumor virus (MuMTV) has been suggested from several
observations. RNA partially homologous to the MuMTV ge-
nome was identified in human breast cancer tissue (1). Lym-
phocytes from individuals with breast cancer were shown to
proliferate after stimulation by MuMTV (2, 3). Sera from breast
cancer patients decreased the infectivitity of MuMTV in mice
(4), suggesting the presence of antibodies against the virus.
More recently, using immunoperoxidase staining, Mesa-Tejada
et al. (5) found that antigen reacting with antibody to the en-
velope glycoprotein of MuMTV (gp52) could be detected in
breast cancer tissue. Ohno et al. (6) have now demonstrated that
this crossreactivity is directed to the protein moiety ofgp52 and
not the carbohydrate.
In prior studies using a virolytic assay with complement and
antibody, we found that antibodies reactive with MuMTV are
present in sera of approximately 20% ofAmerican women with
breast cancer (7). Sera of age-matched healthy women and of
patients with other cancers had such antibodies in lower fre-
quency. We developed a method to detect these antibodies
directly by using MuMTV and an enzyme-linked immunosor-
bent assay (ELISA) (8). With this method also we found that sera
of approximately 25% of American women with breast cancer
had antibodies to MuMTV. Approximately 10% ofwomen with
benign cystic disease of the breast also had such antibodies in
their sera (8). Reactivity was inhibited by the membrane pro-
teins of MuMTV (gp52 and gp34) but not by the core antigen
(p28) (9).
We now report results on the specificity of the human anti-
body for MuMTV, the geographic distribution of the antibody
in breast cancer patients, and analyses of families in which
breast cancer occurred in high frequency.
MATERIAL AND METHODS
Patient Population. The breast cancer patients used for our
study were Caucasian women from the United States, Black
women from Kenya (East Africa), Chinese women from Peking
(People's Republic of China), and Muslim, Parsi, Sindhi, and
Maharashtrian women from Bombay (India). In addition, we
studied individuals from American and Parsi families with high
propensity of breast cancer. The distribution of patients with
breast cancer was as follows: 145 from the United States, 53 from
India, 24 from China, and 21 from East Africa.
Patient Sera. Blood samples (5-10 ml) without anticoagulants
were drawn under sterile conditions and the sera were prepared
by established procedures (10), divided into 100-,ul aliquots,
and stored at - 70°C. Sera from abroad were shipped to the
United States in dry ice.
Viruses and Purified Preparation of the Virus. MuMTV was
purified from cultures ofMuMT-73 murine mammary epithelial
cell line as described (11). gp52, the purified membrane anti-
gen, was prepared according to published procedures (12). AKR
and Rauscher murine leukemia viruses were purified as de-
scribed for the MuMTV.
Determination ofAntibody toMuMTV by ELISA. Sera were
assayed by ELISA for presence of antibody reactive with
MuMTV by described methods (8). Briefly, sera were diluted
1:30 in phosphate-buffered saline containing 0.05% Tween 20
(PJNaCl/Tween) and incubated in microtiter plate wells con-
taining 0.5 ,ug of fixed MuMTV. After 2 hr, the wells were
washed with PJNaCI/Tween, and alkaline phosphatase-con-jugated swine anti-human IgG (Orion Diagnostics, Helsinki,
Finland) was added to the wells. After 120 min, the wells were
again washed with PJNaCl/Tween and the alkaline phospha-
tase substrate p-nitrophenyl phosphate was added. After 30-60
min, the reaction was stopped with 3 M NaOH and the absor-
bance of the yellow color was determined at 400 nm in a spec-
trophotometer. The observed absorbance is proportional to
viral protein over the range 0.1-10 ,ug, and rabbit antibody to
MuMTV is readily detectable at dilutions up to 1:3000 (8).
Absorption Studies. To 50 A.1 of purified MuMTV (0.1 mg/
ml) was added 50 .1l of 1:10 dilution (Pj'NaCl) of heated (56°C,
Abbreviations: MuMTV, murine mammary tumor virus; ELISA, en-
zyme-linked immunosorbent assay; P,/NaCl/Tween, phosphate-buff-
ered saline containing 0.05% Tween 20.
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30 min) test serum with positive antibody titer determined by
the ELISA. The reaction mixture was incubated at 37C for 60
min. The mixture was centrifuged at 10,000 X g for 5 min and
halfofthe supernatant was removed. This process was repeated
three times and the supernatants were analyzed by the ELISA.
The above procedure was repeated with the AKR and Rauscher
murine leukemia and purified gp52.
Absorption with erythrocytes from human, sheep, bovine,
equine, and guinea pig sera was carried out as above with equal
volumes ofwashed (three times) erythrocytes ofvarious species
(1 X 108/ml) and serum.
Blocking Studies. High-titered antisera were incubated with
MuMTV or AKR murine leukemia virus (0. 5 mg/ml) or various
carbohydrates (1 mg/ml) in a final volume of 150 /.l and incu-
bated at 370C for 60 min and at 40C for 18 hr. After centrifu-
gation, the supernatants were assayed by the ELISA for binding
to MuMTV.
Analysis of Results. The results are expressed (a) as the per-
centage of patients in each group with increased levels of an-
tibody to MuMTV (background absorbance of sera of50 healthy
women .0.4) at 1:30 dilution and (b) as the mean of individual
values of antibody to MuMTV. The two-sample t test was used
to detect differences between mean MuMTV antibody levels
ofbreast cancer and healthy groups ofeach nationality. One-way
analysis ofvariance was used to detect differences among mean
MuMTV antibody levels ofhealthy groups ofthree nationalities,
among breast cancer groups of four nationalities, and among
breast cancer groups of three East Indian communities in the
Bombay area. Multiple comparisons by Fisher's least significant
difference procedure were made when appropriate.
RESULTS
Specificity of Antibody in Serum of Patients with Breast
Cancer. Fig. 1 is representative of results of absorption studies
carried out with diluted (1:10) sera from several patients with
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FIG. 1. Absorption of human antibodies reactive with MuMTV.
Aliquots ofMuMTV were incubated with fetal calf serum (A), sheep
erythrocytes (W), Rauscher murine leukemia virus (v), MuMTV (A), or
the MuMTV surface glycoprotein gp52 (v). The supernatants from each
of three consecutive such absorptions (I, II, III) were assayed for IgG
reactivity with MuMTV by ELISA. A at 400 nm refers to the absor-
bance of the yellow color formed by the reaction of alkaline phospha-
tease-conjugated swine anti-human IgG with p-nitrophenyl phos-
phate.The decreases in absorbance resulting from three absorptions
were: fetal calf serum, 4%; sheep erythrocytes, 24%; Rauscher murine
leukemia virus, 26%; MuMTV, 85%; gp52, 96%.
breast cancer who have high levels of antibody reactive with
MuMTV. The antibody was readily absorbed with purified
MuMTV and the envelope glycoprotein of the virus. In con-
trast, fetal calf serum or sheep erythrocytes [or erythrocytes
from cows, horses, guinea pigs, pigs, or humans (not shown)]
failed to absorb the antibody in this way.
Preincubation ofthe serum with MuMTV prevented binding
of the antibody to MuMTV coated on microtiter plates (Fig. 2).
In contrast, preincubation with glycogen or another murine ret-
rovirus, the type C AKR leukemia virus, did not prevent the
binding of the antibody to MuMTV. Similar results were ob-
tained when D-galactose, N-acetyl-D-galactosamine, L-fucose,
or D-mannose were substituted for glycogen (data not shown).
Furthermore, no significant changes in background binding
were observed after absorption ofnormal serum with MuMTV,
gp52, or various erythrocytes.
Geographical Study of Antibody in Sera of Patients with
Breast Cancer. Fig. 3 summarizes the binding to MuMTV of
specific IgG from sera of breast cancer patients from several
different geographical regions. Increased levels of antibody to
MuMTV (absorbance .0.4) were found in sera of 27 of 145
(18.6%) patients from the United States, 20 of 53 from India
(37.7%), and 13 of 21 from Kenya (61.9%). In striking contrast
to the high frequency of positive antibody levels observed in
sera of patients from Kenya, less than 5% of sera from Chinese
patients had antibody reactive with MuMTV. Sera of the
Chinese breast cancer patients who were positive for MuMTV
exhibited antibody levels lower than those in the American,
East African, and East Indian patients. Hence, differences in
MuMTV antibody levels among breast cancer patients of these
four nationalities were found to be significant (F, with 3 and 239
degrees of freedom, = 9.12; P < 0.0001).
Distributions of individual MuMTV antibody levels in sera
ofbreast cancer patients from three different communities from
the Bombay region are summarized below. The Sindhi group
was omitted from the statistical considerations because only
three Sindhi women with breast cancer were included in the
study (only one had an increased level). Increased levels of
MuMTV antibody were found in 1 of 14 Parsi women (7.1%),
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FIG. 2. Effect of MuMTV, AKR leukemia virus, and glycogen on
the reactivity of human breast cancer serum with MuMTV. Aliquots
of sera from breast cancer patients were incubated with 0-10 jig of
MuMTV (m), AKR virus (-), or glycogen (A) and the supernatants were
assayed for IgG binding to MuMTV, as described in Fig. 1.
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FIG. 3. Antibody reactive with MuMTV in sera of breast cancer
patients from the United States, East Africa, China, and India. A 2
0.4 was considered to be significant.
FIG. 4. Antibody reactive with MuMTV in sera of healthy indi-
viduals from the United States, East Africa, and China.
P = 0.016) (Fig. 5) and between healthy East African women
and East African women with breast cancer (means, 0.3157 and
0.4694, respectively; F, with 45 degrees of freedom, = 2.11;
P = 0.04) (data not shown).
Family Studies of Antibody to MuMTV. Fig. 6 shows a rep-
resentative American family pedigree in which breast cancer
occurred in several family members. Breast cancer had oc-
curred in both maternal and paternal relatives. Neither the
5 of 12 Muslim women (41.7%), and 13 of 24 Maharashtrian
women (54.2%). Differences in the mean ofindividual antibody
levels among the three groups were found to be significant (F,
with 2 and 4.7 degrees of freedom, = 3.396; P = 0.04). The
mean level was 0.2115 in the Parsi group, 0.4809 in the Ma-
harashtrian group, 0.3407 in the Muslim; the first two means
were significantly different from each other but the third was
not significantly different from either (P = 0.05; Fisher's least
significant difference procedure).
Sera from healthy women of several nationalities were also
compared. Increased levels of antibody to MuMTV were found
in 1 of 22 healthy Chinese women (4.5%), 1 of 36 healthy
American women (2.8%), and 7 of 26 healthy East African
women (26.9%) (Fig. 4). The mean levels of antibody reactive
to MuMTV in sera of healthy Chinese, American, East African,
and East Indian women were also compared. The four groups
were found to be significantly different (F, with 3 and 104 de-
grees of freedom, = 11.9; P < 0.0001). Specifically, the East
Indian group had significantly higher mean levels of MuMTV
antibody than the other three groups (mean, 0.5580). More-
over, the American group had significantly lower mean level
of antibody to MuMTV (mean, 0.1851) than the East African
group (mean, 0.3157); the mean of the Chinese group (mean,
0.2267) was between the American and East African means but
was not significantly different from either (P = 0.05; Fisher's
least significant difference procedure). No significant difference
was found between levels of antibody to MuMTV in sera of
healthy Chinese women and Chinese women with breast cancer
(means, 0.2267 and 0.2424, respectively). In contrast, signifi-
cant differences were found between healthy American women
and American women with breast cancer (means, 0.1832 and
0.2568, respectively; F, with 179 degrees of freedom, = 2.43;
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FIG. 5. Comparison of serum levels of antibody to MuMTV in
healthy Chinese and American women and breast cancer patients.
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FIG. 6. Antibodies reactive with MuMTV in a family with a his-
tory of breast cancer. Sera from three generations of a family with a
history of breast cancer were assayed for antibody to MuMTV by the
ELISA. The numbers refer to the absorbance at 400 nm (see Fig. 1 for
explanation); A 2 0.4 is positive for MuMTV antibody, o, female; 0,
female with breast cancer; a, female with other cancer; n, male; t,
deceased.
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FIG. 8. Antibody to MuMTV in sera of one Parsi family with ge-
netic propensity to breast cancer in family members.
father nor the mother of the propositus had breast cancer but
both had significantly increased titers of antibody to MuMTV.
Furthermore, in each ofthese the antibody was absorbable with
MuMTV and gp52. All siblings (both male and female) of the
propositus had increased titers ofantibody and in each case the
antibody was absorbable with MuMTV and gp52.
In two other American families with high frequency of breast
cancer (Fig. 7), 33% of the members of family I and 71% of
members of family II showed an increased titer of antibody to
MuMTV. In family I the patients' sera did not show increased
antibody levels whereas in family II, the patients' serum did.
Similar observations of frequently increased levels of anti-
body reactive to MuMTV were observed in family members of
Parsi women with a high frequency of breast cancer. A repre-
sentative Parsi family is illustrated in Fig. 8. In this family, 23%
of healthy relatives had increased levels of antibody reactive
with MuMTV.
DISCUSSION
Much evidence links immune responses in human breast cancer
to antigens represented in MuMTV. The findings from our pres-
ent geographical and family study support the hypothesis that
a relationship exists between antibodies reactive with MuMTV
and breast cancer in humans. Some patients with breast cancer
react to antigens that are at least crossreactive with antigens
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FIG. 7. Antibody toMuMTV in sera oftwo American families with
genetic propensity to breast cancer in family members. n, Healthy
male; o, healthy female; *, female with breast cancer; Q, female with
benign breast disease.
represented on MuMTV, especially the envelope glycoprotein
gp52. Various erythrocytes and other murine tumor viruses did
not yield signficant absorption of the antibody under study.
Futhermore, blocking of binding of antibody to MuMTV ad-
herent to microtiter plates was not inhibited by glycogen or
other sugars found in cell membranes but was completely in-
hibited by MuMTV.
These findings do not exclude the possibility that antibodies
against heterophile antigens related to the virus may also occur
in sera ofpatients with breast cancer. Antibodies in human sera
to the glycoprotein of type C retroviruses appear to be directed
to the sugar moiety (13).
Several possibilities must be considered to explain our find-
ings, of which one is that a virus or viruses related to MuMTV
play a role in some patients with breast cancer. More likely is
the possibility that gene sequences related to those determining
MuMTV proteins are expressed in some patients with human
breast cancer and that antibodies or autoantibodies to these
antigenic determinants are sometimes made in humans with
certain forms of breast cancer.
Perhaps the most striking of the findings in this report is that
major differences in these antibody responses were found when
sera of breast cancer patients from different parts of the world
were investigated. Sera ofwomen from Kenya with breast can-
cer had these antibodies in highest frequency and highest titers
followed, in turn, by sera of breast cancer patients from East
India, America, and China. The Chinese women with breast
cancer had both the lowest titers and the lowest frequency of
increased titers. The simplest interpretation ofthese data is that
there exist multiple (at least two) separate forms ofbreast cancer
and in one, antigens stimulate production of the anti-MuMTV
antibodies. It is of interest in this regard that Levine et al. (14)
recently demonstrated, by immunoperoxidase assay, an antigen
that crossreacts immunohistochemically with gp52 of the
MuMTV in large quantities in 70% of biopsy specimens (23/
33) from Tunisian breast cancer patients compared with 47%
ofAmerican breast cancer biopsy speciments. In contrast, even
significantly less antigen was present in Japanese breast cancer
biopsies (Sol Spiegelman, Columbia University, New York,
personal communication). The parallel with our observations,
and thus the complementarity of the two findings, is obvious.
That genetic factors or factors in the immediate environment
play a role in the expression of the antigenic stimulation that
leads to the antibody response under study is suggested by the
reported observations that breast cancer patients who are mem-
bers of different communities in the Bombay area of India ex-
press these antibodies in different frequencies. These findings
require more penetrating analysis.
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The findings from our studies of American and East Asian
families in which breast cancer occurs in high frequency are also
challenging. They show that increased titers ofantibody against
MuMTV can occur in healthy female family members and even
in some males. The latter antibodies also were absorbable with
the virus and gp52. These family studies must be pursued in
greater depth but they suggest the possibility that members at
risk for breast cancer in such families may be identifiable by
immunological analyses prior to the development or full expres-
sion of the breast cancer.
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